TASK ORDER 07 (75N95022F00001) FOR IDIQ HHSN271201800024I WITH EUROFINS PANLABS DISCOVERY SERVICES

此次收购的目的是继续作为国家药物滥用研究所(NIDA)既定合同的一个主要组成部分，即NIDA/治疗和医疗后果司(DTMC)/成瘾治疗发现计划(ATDP)。该计划需要内部能力对各种受体靶标进行体外受体结合分析，并使用适当的体外生物系统进行后续结合和功能分析，以及体外预测毒理学分析。

The objective of this acquisition is to continue a major component of the National Institute on Drug Abuse’s (NIDA) established contracts, the NIDA/Division of Therapeutics and Medical Consequences (DTMC)/Addiction Treatment Discovery Program (ATDP). The program requires in-house capability to perform in vitro receptor binding assays on a wide variety of receptor targets, and perform follow-up binding and functional assays using appropriate in vitro biological systems, in addition to in vitro predictive toxicology assays.